Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace
NCT03272685Phase 3Completed
- Sponsor
- University of Minnesota
- Start
- Jun 2018
- Primary completion
- Sep 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cigarette reduced nicotine in nicotine dependence and Tobacco Use Disorder (TUD) (2 arms), sponsored by University of Minnesota. Primary endpoints: Cigarettes Per Day and Number of Smoke-free Days. Started Jun 2018; status: completed.
02
Drugs
cigarette reduced nicotine
03
Conditions
nicotine dependenceTobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03272685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272685.